There’s something disorienting about sitting in an oncologist’s office, waiting for answers. Whether it’s the first time or the tenth, the weight in the air is the same. Families cling to hope, doctors search for protocols, and patients try to understand what comes next. But far too often, a critical treatment path is left unspoken—not because it’s unavailable, but because no one brings it up. That path is clinical trials. And though these trials have led to some of the most important breakthroughs in modern oncology—from targeted therapies to immunotherapies—they remain misunderstood, underutilized, and deeply under-discussed. Despite decades of progress, fewer than 5% of adult cancer patients in the U.S. participate in clinical trials. And according to new research, only 15% of survivors even recall their doctors discussing the option with them. In communities of color, awareness and access are even lower, creating a cycle of missed opportunities and silent exclusion. The imp...